Skip to content
thestock.space

Alivus Life Sciences (ALIVUS) had a P/E of 27.2× on 6 Nov 2026, below the industry P/E of 28.7×. It earns ROCE of 22% and ROE of 20%, and sales and net profit grew 6.9% and 6.5% a year over 3 years. It has almost no debt, and its dividend yield is 0.3%. It is a small-cap company with a market cap of ₹18,207 Cr, ranked 24th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 66% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,497.20
Day high
₹1,523.20
Day low
₹1,403.40
Prev. close
₹1,497.20
Volume
15.8 L

Health check

4 good · 1 fair · 1 to check
  • ReturnsAhead

    +65.6% over a year, better than 6 of 7 peers.

  • Price tagIn line

    P/E 27.2 vs industry 28.7.

  • GrowthSlow

    Sales +6.9%, profit +6.5% a year over 3 years.

  • ProfitabilityStrong

    ROCE 21.8% vs peer median 17.9%.

  • Balance sheetSolid

    Practically debt-free.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹18,207 Cr, #24 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹2,684 Cr · profit ₹670 Cr
Market cap
₹18,207 Cr
Small cap
P/E
27.2
Industry 28.7
Price to book
5.01
Peers 4.99
Dividend yield
0.34%
ROE
20.2%
Peers 14.7%
ROCE
21.8%
Peers 17.9%
Debt to equity
0.01
Debt ₹53 Cr
EPS (TTM)
₹54.43
Face value ₹2
OPM (TTM)
34.4%
Net margin 24.9%
Sales growth
+16.0%
Latest quarter vs a year ago
Profit growth
+50.8%
Latest quarter vs a year ago
Price to sales
6.78
EV/EBITDA 18.9

Strengths and risks

Strengths

  • Return on equity of 20.2%.
  • Return on capital employed of 21.8%.
  • Practically debt-free.
  • Quarterly profit up 50.8% on a year ago.
  • Quarterly sales up 16.0% on a year ago.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Alivus Life Sciences

Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes,…

Headquarters
Mumbai
Employees
2,272
Sector
Healthcare
ISIN
INE03Q201024
Website
alivus.com

Price range

52 weeks

₹819.00₹1,546.00

Today

₹1,403.40₹1,523.20
Avg volume (3M)
2 L
1-year return
plus 65.6%
From 52-week high
minus 4.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
ALIVUSAlivus Life Sciences1,480.60minus 1.11%18,20727.25.01–20.2%35.7%––0.34%plus 65.6%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
602673689640682
430442475429417
172231215212265
28.6%34.4%31.1%33.1%38.9%
913.922.822.419.9
1.31.51.31.31.3
17.119.720.220.621.8
–−25.7–––
163198216212262
25.4%24.3%24.6%24.6%24.9%
122150163160197
9.8812.2213.2213.0115.98

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+6.9%
Profit CAGR 3Y
+6.5%
EPS CAGR 3Y
+6.4%
ROE
20.2%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,0482,1852,3402,504
–+6.7%+7.1%+7.0%
1,4051,5091,6551,706
643676684798
31.4%30.9%29.3%31.9%
2911.42722.4
0.51.52.45.4
42.153.560.675.4
−0.6−0.75.811.9
629631654751
25.7%25.4%25.8%24.9%
467471486564
–+0.8%+3.1%+16.2%
38.1138.3839.5245.90

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
24.524.524.524.5
2,1142,3082,7933,308
19.417.156.656.8
545501537594
2,7022,8503,4113,983
8269051,0461,297
50.6110103279
0.10.10.10.1
284301549782
1,5421,5341,7141,625
2,7022,8503,4113,983

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
306414392565
−147−116−616−570
−388−279−6.2−64.3
−22817.6−230−69.1
−163−129−166−307
143285225258
−386−276–−61.3

Shareholding pattern

Source: NSE filings
74.8%
promoters
  • Promoters74.85%
  • Public25.15%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202674.85%25.15%minus 0.02
30 Jun 202674.87%25.13%0.00
31 Mar 202674.87%25.13%minus 0.04
31 Dec 202574.91%25.09%0.00
30 Sep 202574.91%25.09%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you